Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Abstract CT164: Phase 1a/1b clinical trial of LP-284, a highly potent TP53 mutation agnostic DNA damaging agent, in patients with refractory or relapsed lymphomas and solid tumors (NCT06132503)

Jianli Zhou, Reginald Ewesuedo, Giulia Agnello, Aditya Kulkarni, Kishor Bhatia

Cancer Res (2024) 84 (7_Supplement): CT164.

https://doi.org/10.1158/1538-7445.AM2024-CT164

Published: 05 April 2024

View article titled, Abstract CT164: Phase 1a/1b clinical trial of LP-284, a highly potent TP53 mutation agnostic DNA damaging agent, in patients with refractory or relapsed lymphomas and solid tumors (NCT06132503)

Journal Articles

Ian Magrath, MD: In Memoriam (1944–2023)

Kishor Bhatia

Cancer Res (2023) 83 (16): 2635–2636.

https://doi.org/10.1158/0008-5472.CAN-23-2078

Published: 15 August 2023

View article titled, Ian Magrath, MD: In Memoriam (1944–2023)

Journal Articles

Abstract 6241: LP-184, an acylfulvene class small molecule therapeutic, is synthetically lethal in DNA damage repair deficient cancers

Aditya Kulkarni, Jianli Zhou, Neha Biyani, Kishor Bhatia, Panna Sharma

Cancer Res (2023) 83 (7_Supplement): 6241.

https://doi.org/10.1158/1538-7445.AM2023-6241

Published: 04 April 2023

View article titled, Abstract 6241: LP-184, an acylfulvene class small molecule therapeutic, is synthetically lethal in DNA damage repair deficient cancers

Journal Articles

Abstract P4-01-06: LP-184, an acylfulvene class small molecule therapeutic, is synthetically lethal in HR deficient and PARP inhibitor resistant triple negative breast cancer

Aditya Kulkarni, Neha Biyani, Laura Brullé-Soumaré, Stefano Cairo, Panna Sharma, Kishor Bhatia

Cancer Res (2023) 83 (5_Supplement): P4-01-06.

https://doi.org/10.1158/1538-7445.SABCS22-P4-01-06

Published: 01 March 2023

View article titled, Abstract P4-01-06: LP-184, an acylfulvene class small molecule therapeutic, is synthetically lethal in HR deficient and PARP inhibitor resistant triple negative breast cancer

Journal Articles

Abstract B033: LP-184, a tumor site activated small molecule therapeutic, is synthetically lethal in pancreatic cancers with DNA damage repair defects

Aditya Kulkarni, Diana Restifo, Troy Dos Santos, Dusica Cvetkovic, Joseph McDermott, Kishor Bhatia, Panna Sharma, Charlie Ma, Igor Astsaturov

Cancer Res (2022) 82 (22_Supplement): B033.

https://doi.org/10.1158/1538-7445.PANCA22-B033

Published: 15 November 2022

View article titled, Abstract B033: LP-184, a tumor site activated small molecule therapeutic, is synthetically lethal in pancreatic cancers with DNA damage repair defects

Journal Articles

Abstract PO-036: LP184, a novel alkylating agent, is highly effective in pancreatic cancers with DNA damage repair defects

Diana Restifo, Aditya Kulkarni, Caleb Schimke, Joseph McDermott, Umesh Kathad, Kishor Bhatia, Panna Sharma, Igor Astsaturov

Cancer Res (2021) 81 (22_Supplement): PO-036.

https://doi.org/10.1158/1538-7445.PANCA21-PO-036

Published: 15 November 2021

View article titled, Abstract PO-036: LP184, a novel alkylating agent, is highly effective in pancreatic cancers with DNA damage repair defects

Journal Articles

Abstract 1249: LP184, a novel alkylating agent, is efficacious in prostate cancer models with DNA damage repair defects

Aditya Kulkarni, Partha Banerjee, Umesh Kathad, Kishor Bhatia, Panna Sharma

Cancer Res (2021) 81 (13_Supplement): 1249.

https://doi.org/10.1158/1538-7445.AM2021-1249

Published: 01 July 2021

View article titled, Abstract 1249: LP184, a novel alkylating agent, is efficacious in prostate cancer models with DNA damage repair defects

Journal Articles

Abstract 2090: Machine learning-derived gene signature predicts strong sensitivity of several solid tumors to the alkylating agent LP-184

Umesh Kathad, Aditya Kulkarni, Jean Philippe Richard, Terri Lehman, Rama Modali, Kishor Bhatia, Panna Sharma, Fathi Elloumi, Yves Pommier, William C. Reinhold

Cancer Res (2020) 80 (16_Supplement): 2090.

https://doi.org/10.1158/1538-7445.AM2020-2090

Published: 15 August 2020

View article titled, Abstract 2090: Machine learning-derived gene signature predicts strong sensitivity of several solid tumors to the alkylating agent LP-184

Journal Articles

Abstract 4490: Molecular characteristics of diffuse large B-cell lymphoma in HIV-positive and HIV-negative patients

Clara J. Kim, Wendy Cozen, Lawrence M. Weiss, Kishor Bhatia, Myles Cockburn, Debra Hawes, Sophia S. Wang, Eric A. Engels, Lindsay M. Morton

Cancer Res (2012) 72 (8_Supplement): 4490.

https://doi.org/10.1158/1538-7445.AM2012-4490

Published: 15 April 2012

View article titled, Abstract 4490: Molecular characteristics of diffuse large B-cell lymphoma in HIV-positive and HIV-negative patients

Journal Articles

Abstract 3744: Risk of esophageal and stomach malignancies in people with AIDS

E. Christina Persson, Meredith S. Shiels, Kishor Bhatia, Sanford M. Dawsey, Eric A. Engels

Cancer Res (2011) 71 (8_Supplement): 3744.

https://doi.org/10.1158/1538-7445.AM2011-3744

Published: 15 April 2011

View article titled, Abstract 3744: Risk of esophageal and stomach malignancies in people with AIDS

Journal Articles

Bax Is Frequently Compromised in Burkitt’s Lymphomas with Irreversible Resistance to Fas-induced Apoptosis

Marina I. Gutiérrez, Barry Cherney, Azhar Hussain, Howard Mostowski, Giovanna Tosato, Ian Magrath, Kishor Bhatia

Cancer Res (1999) 59 (3): 696–703.

Published: 01 February 1999

View article titled, Bax Is Frequently Compromised in Burkitt’s Lymphomas with Irreversible Resistance to Fas-induced Apoptosis

Journal Articles

Relationships between G₁ Arrest and Stability of the p53 and p21^Cip1/Waf1 Proteins following γ-Irradiation of Human Lymphoma Cells

Insoo Bae, Saijun Fan, Kishor Bhatia, Kurt W. Kohn, Albert J. Fornace, Jr., Patrick M. O'Connor

Cancer Res (1995) 55 (11): 2387–2393.

Published: 01 June 1995

View article titled, Relationships between G1 Arrest and Stability of the p53 and p21Cip1/Waf1 Proteins following γ-Irradiation of Human Lymphoma Cells

Journal Articles

A Mutant p21 Cyclin-dependent Kinase Inhibitor Isolated from a Burkitt's Lymphoma

Kishor Bhatia, Saijun Fan, Gordon Spangler, Michael Weintraub, Patrick M. O'Connor, Jean-Gabriel Judde, Ian Magrath

Cancer Res (1995) 55 (7): 1431–1435.

Published: 01 April 1995

View article titled, A Mutant p21 Cyclin-dependent Kinase Inhibitor Isolated from a Burkitt's Lymphoma

Journal Articles

p53 Gene Mutations Are Associated with Decreased Sensitivity of Human Lymphoma Cells to DNA Damaging Agents

Saijun Fan, Wafik S. El-Deiry, Insoo Bae, Jim Freeman, Daniel Jondle, Kishor Bhatia, Albert J. Fornace, Jr., Ian Magrath, Kurt W. Kohn, Patrick M. O'Connor

Cancer Res (1994) 54 (22): 5824–5830.

Published: 01 November 1994

View article titled, p53 Gene Mutations Are Associated with Decreased Sensitivity of Human Lymphoma Cells to DNA Damaging Agents

Journal Articles

Role of the p53 Tumor Suppressor Gene in Cell Cycle Arrest and Radiosensitivity of Burkitt's Lymphoma Cell Lines

Patrick M. O'Connor, Joany Jackman, Daniel Jondle, Kishor Bhatia, Ian Magrath, Kurt W. Kohn

Cancer Res (1993) 53 (20): 4776–4780.

Published: 01 October 1993

View article titled, Role of the p53 Tumor Suppressor Gene in Cell Cycle Arrest and Radiosensitivity of Burkitt's Lymphoma Cell Lines

Journal Articles

Infrequent p53 Mutation in Mouse Tumors with Deregulated myc

Marina I. Gutierrez, Kishor Bhatia, David Siwarski, Linda Wolff, Ian T. Magrath, J. Frederic Mushinski, Konrad Huppi

Cancer Res (1992) 52 (4): 1032–1035.

Published: 01 February 1992

View article titled, Infrequent p53 Mutation in Mouse Tumors with Deregulated myc

NARROW

Abstract CT164: Phase 1a/1b clinical trial of LP-284, a highly potent TP53 mutation agnostic DNA damaging agent, in patients with refractory or relapsed lymphomas and solid tumors (NCT06132503)

Ian Magrath, MD: In Memoriam (1944–2023)

Abstract 6241: LP-184, an acylfulvene class small molecule therapeutic, is synthetically lethal in DNA damage repair deficient cancers

Abstract P4-01-06: LP-184, an acylfulvene class small molecule therapeutic, is synthetically lethal in HR deficient and PARP inhibitor resistant triple negative breast cancer

Abstract B033: LP-184, a tumor site activated small molecule therapeutic, is synthetically lethal in pancreatic cancers with DNA damage repair defects

Abstract PO-036: LP184, a novel alkylating agent, is highly effective in pancreatic cancers with DNA damage repair defects

Abstract 1249: LP184, a novel alkylating agent, is efficacious in prostate cancer models with DNA damage repair defects

Abstract 2090: Machine learning-derived gene signature predicts strong sensitivity of several solid tumors to the alkylating agent LP-184

Abstract 4490: Molecular characteristics of diffuse large B-cell lymphoma in HIV-positive and HIV-negative patients

Abstract 3744: Risk of esophageal and stomach malignancies in people with AIDS

Bax Is Frequently Compromised in Burkitt’s Lymphomas with Irreversible Resistance to Fas-induced Apoptosis

Relationships between G₁ Arrest and Stability of the p53 and p21^Cip1/Waf1 Proteins following γ-Irradiation of Human Lymphoma Cells

A Mutant p21 Cyclin-dependent Kinase Inhibitor Isolated from a Burkitt's Lymphoma

p53 Gene Mutations Are Associated with Decreased Sensitivity of Human Lymphoma Cells to DNA Damaging Agents

Role of the p53 Tumor Suppressor Gene in Cell Cycle Arrest and Radiosensitivity of Burkitt's Lymphoma Cell Lines

Infrequent p53 Mutation in Mouse Tumors with Deregulated myc

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only